Cholangitis Market by Products (Ursodeoxycholic Acid, Obeticholic Acid, and Others), Technology (Computed Tomography, Transabdominal Ultrasound, Magnetic Resonance Imaging, Endoscopic Retrograde Cholangiopancreatography, Endoscopic Ultrasound, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028
The global cholangitis market size is estimated to register a considerable CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the growing geriatric population base. Moreover, increasing healthcare awareness among people regarding the disease and change in lifestyle are key factors anticipated to fuel the market growth.
When inflammation occurs due to infection in the bile duct system of an individual, it is known as cholangitis. Bile juice, which is helpful in digestion, gets carried by the bile duct also known as the biliary tract from the liver to the intestine and the gallbladder. Cholangitis happens due to a bacterial infection. The infection in the bile duct sometimes also leads to morbidity or mortality. Some of the common symptoms associated with cholangitis include fever, jaundice, abdominal pain, and low blood pressure. However, the risk of cholangitis increases to a great extent if an individual is suffering from pancreatic cancer.
It is very important to get cholangitis diagnosed and treated at the early stage as the delay can increase the chances of severe consequences. When less bile juice is secreted and the prime fat-soluble vitamins do not get absorbed into the body, it causes cholangitis. The infection, without proper precautions, can result to bile duct cancer and liver failure. Cholangitis is a very common disorder among the geriatric population base; however, it is not very common among the population under the age of 40. The effect of this disorder differs from person to person and various methods that can be used for the detection of this disorder.
Market Trends, Drivers, Restraints, and Opportunities
- Wide prevalence of disorders related to liver and increasing cases of cholangitis are anticipated to fuel the market growth during the forecast period.
- Availability of affordable healthcare diagnosis & treatment for the disorder is expected to propel the market growth during the forecast period.
- Lack of awareness of the disease treatment among the targeted population is anticipated to restrain the market growth.
- Strict regulatory policies imposed by governments for the approval of newly launched products is estimated to be a key factor that can hinder the market expansion.
- Increasing research & development activities for the development of new drugs for cholangitis is projected to create lucrative opportunities for market growth.
Scope of the Report
The report on the global cholangitis market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Cholangitis Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Products (Ursodeoxycholic Acid, Obeticholic Acid, and Others) and Technology (Computed Tomography, Transabdominal Ultrasound, Magnetic Resonance Imaging, Endoscopic Retrograde Cholangiopancreatography, Endoscopic Ultrasound, and Others) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Zambon Company SPA; Mayo Clinic; Riemser Arzneimittel; Gilead Sciences; Bayer AG; and Taiho Pharmaceutical Co. Ltd. |
Market Segment Insights
Ursodeoxycholic acid segment is expected to grow at a rapid pace
On the basis of products, the global cholangitis market is segmented into ursodeoxycholic acid, obeticholic acid, and others. The ursodeoxycholic acid segment is expected to grow at a rapid pace during the forecast period owing to rising demand for the product ad increasing its usage for the treatment. The methodology used for the treatment of cholangitis depends on the condition of how severe the disease has affected the patient.
Endoscopic ultrasound segment is anticipated to expand at a lucrative growth rate
Based on technology, the market is divided into computed tomography, transabdominal ultrasound, magnetic resonance imaging, endoscopic retrograde cholangiopancreatography, endoscopic ultrasound, and others. The endoscopic ultrasound segment is anticipated to expand at a lucrative growth rate during the projected period attributed to its wide adoption as an alternative to percutaneous transhepatic cholangiography. The latter technology is extensively used for the second-line therapy in cases where endoscopic retrograde cholangiopancreatography fails.
North America is estimated to dominate the market
In terms of regions, the global cholangitis market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is estimated to dominate the market in the coming years owing to increasing awareness regarding healthcare among patients coupled with a growing geriatric population base in the region. However, the market of Asia Pacific is anticipated to grow at a considerable rate due to increasing awareness regarding the disease and rising disposable income of a large number of the regional population.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cholangitis Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cholangitis Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cholangitis Market - Supply Chain
4.5. Global Cholangitis Market Forecast
4.5.1. Cholangitis Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cholangitis Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Cholangitis Market Absolute $ Opportunity
5. Global Cholangitis Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Cholangitis Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Cholangitis Demand Share Forecast, 2019-2026
6. North America Cholangitis Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Cholangitis Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Cholangitis Demand Share Forecast, 2019-2026
7. Latin America Cholangitis Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Cholangitis Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Cholangitis Demand Share Forecast, 2019-2026
8. Europe Cholangitis Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Cholangitis Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Cholangitis Demand Share Forecast, 2019-2026
9. Asia Pacific Cholangitis Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Cholangitis Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Cholangitis Demand Share Forecast, 2019-2026
10. Middle East & Africa Cholangitis Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Cholangitis Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Cholangitis Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Cholangitis Market: Market Share Analysis
11.2. Cholangitis Distributors and Customers
11.3. Cholangitis Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Zambon Company SPA
11.4.2. Mayo Clinic
11.4.3. Riemser Arzneimittel
11.4.4. Gilead Sciences
11.4.5. Bayer AG
11.4.6. Taiho Pharmaceutical Co. Ltd.